Tango Therapeutics, Inc. Payments to Acquire Marketable Securities
Tango Therapeutics, Inc. (TNGX) reported Payments to Acquire Marketable Securities of $573.51 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-11
- Tango Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2026-06-30 was $519.10M, a 2068.68% increase year-over-year.
- Tango Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2026-03-31 was $54.41M, a 15.37% increase year-over-year.
- Tango Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2025-12-31 was $175.02M, a 437.71% increase year-over-year.
- Tango Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2025-09-30 was $18.34M, a 53.54% decline year-over-year.
- Tango Therapeutics, Inc. payments to acquire marketable securities for fiscal 2025 was $264.46M, a 9.78% increase from fiscal 2024.
- Tango Therapeutics, Inc. payments to acquire marketable securities for fiscal 2024 was $240.89M, a 22.44% decline from fiscal 2023.
- Tango Therapeutics, Inc. payments to acquire marketable securities for fiscal 2023 was $310.57M, a 48.95% increase from fiscal 2022.
- Tango Therapeutics, Inc. payments to acquire marketable securities for fiscal 2022 was $208.50M, a 44.00% decline from fiscal 2021.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $519.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $573.51M 10-Q · filed 2026-08-11 | $748.53M derived: sum of 3 quarters · filed 2026-08-11 | $766.86M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $54.41M 10-Q · filed 2026-05-13 | $229.43M derived: sum of 2 quarters · filed 2026-05-13 | $247.77M derived: sum of 3 quarters · filed 2026-05-13 | $271.70M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $175.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $193.36M derived: sum of 2 quarters · filed 2026-03-05 | $217.29M derived: sum of 3 quarters · filed 2026-08-11 | $264.46M 10-K · filed 2026-03-05 |
| 2025-09-30 | $18.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $42.27M derived: sum of 2 quarters · filed 2026-08-11 | $89.44M 10-Q · filed 2025-11-04 | $121.99M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $23.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $71.10M 10-Q · filed 2026-08-11 | $103.65M derived: sum of 3 quarters · filed 2026-08-11 | $143.11M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $47.16M 10-Q · filed 2026-05-13 | $79.71M derived: sum of 2 quarters · filed 2026-05-13 | $119.18M derived: sum of 3 quarters · filed 2026-05-13 | $167.79M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $32.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $72.01M derived: sum of 2 quarters · filed 2026-03-05 | $120.63M derived: sum of 3 quarters · filed 2026-03-05 | $240.89M 10-K · filed 2026-03-05 |
| 2024-09-30 | $39.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $88.08M derived: sum of 2 quarters · filed 2025-11-04 | $208.34M 10-Q · filed 2025-11-04 | $259.36M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-06-30 | $48.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $168.87M 10-Q · filed 2025-08-05 | $219.90M derived: sum of 3 quarters · filed 2026-03-05 | $376.14M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-03-31 | $120.26M 10-Q · filed 2025-05-12 | $171.29M derived: sum of 2 quarters · filed 2026-03-05 | $327.53M derived: sum of 3 quarters · filed 2026-03-05 | $378.30M derived: sum of 4 quarters · filed 2026-03-05 |
| 2023-12-31 | $51.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $207.26M derived: sum of 2 quarters · filed 2026-03-05 | $258.04M derived: sum of 3 quarters · filed 2026-03-05 | $310.57M 10-K · filed 2026-03-05 |
| 2023-09-30 | $156.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $207.01M derived: sum of 2 quarters · filed 2024-11-06 | $259.55M 10-Q · filed 2024-11-06 | $353.11M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $50.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $103.31M 10-Q · filed 2024-08-07 | $196.87M derived: sum of 3 quarters · filed 2025-02-27 | $241.32M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $52.53M 10-Q · filed 2024-05-08 | $146.09M derived: sum of 2 quarters · filed 2025-02-27 | $190.55M derived: sum of 3 quarters · filed 2025-02-27 | $206.47M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $93.56M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $138.01M derived: sum of 2 quarters · filed 2025-02-27 | $153.93M derived: sum of 3 quarters · filed 2025-02-27 | $208.50M 10-K · filed 2025-02-27 |
| 2022-09-30 | $44.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $60.38M derived: sum of 2 quarters · filed 2023-11-08 | $114.95M 10-Q · filed 2023-11-08 | $219.33M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $15.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $70.49M 10-Q · filed 2023-08-07 | $174.88M derived: sum of 3 quarters · filed 2023-08-07 | $356.74M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $54.57M 10-Q · filed 2023-05-09 | $158.96M derived: sum of 2 quarters · filed 2023-05-09 | $340.81M derived: sum of 3 quarters · filed 2023-05-09 | $407.06M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $104.39M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | $286.24M derived: sum of 2 quarters · filed 2023-03-27 | $352.49M derived: sum of 3 quarters · filed 2023-03-27 | $372.36M 10-K · filed 2023-03-27 |
| 2021-09-30 | $181.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $248.11M derived: sum of 2 quarters · filed 2022-11-10 | $267.98M 10-Q · filed 2022-11-10 | $373.57M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $66.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $86.12M 10-Q · filed 2022-08-10 | $191.71M derived: sum of 3 quarters · filed 2022-08-10 | |
| 2021-03-31 | $19.87M 10-Q · filed 2022-05-11 | $125.47M derived: sum of 2 quarters · filed 2022-05-11 | ||
| 2020-12-31 | $105.60M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $207.54M 10-K · filed 2022-03-28 | ||
| 2020-09-30 | $101.94M 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |